CVS Health(CVS)
Search documents
CVS Health(CVS) - 2025 Q2 - Quarterly Report
2025-07-31 10:34
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to_________ Commission File Number: 001-01011 CVS HEALTH CORPORATION (Exact name of registrant as specified in its charter) | Delaware | 05-0494040 | ...
CVS健康(CVS.N)预期本财年EPS6.30-6.40美元,之前预期6-6.20美元,市场预期6.13美元。
news flash· 2025-07-31 10:33
CVS健康(CVS.N)预期本财年EPS6.30-6.40美元,之前预期6-6.20美元,市场预期6.13美元。 ...
CVS beats estimates, hikes adjusted profit outlook on retail pharmacy and insurance unit strength
CNBC· 2025-07-31 10:32
Core Viewpoint - CVS Health reported stronger-than-expected second-quarter earnings and revenue, leading to an increase in its adjusted profit outlook, driven by the retail pharmacy business and improvements in its insurance unit [1][2]. Financial Performance - The company expects fiscal 2025 adjusted earnings to be between $6.30 and $6.40 per share, an increase from the previous guidance of $6 to $6.20 per share [2]. - CVS reported net income of $1.02 billion, or 80 cents per share, for the first quarter, down from $1.77 billion, or $1.41 per share, in the same period last year [5]. - Adjusted earnings for the quarter were $1.81 per share, exceeding the expected $1.46 per share [8]. - Revenue for the first quarter was $98.92 billion, an 8.4% increase from the previous year, surpassing the expected $94.50 billion [6][8]. Business Segments - The retail pharmacy business is performing well, attributed to new technology and investments in labor, which have improved operations and efficiency [4]. - The insurance unit, Aetna, is undergoing a multi-year recovery effort to address higher medical costs, contributing to the positive outlook [3]. - However, the strength in the retail pharmacy and insurance segments was partially offset by a decline in the health services segment [4]. Strategic Initiatives - CVS is pursuing a broader turnaround plan that includes $2 billion in cost cuts over the next several years, with plans to close additional locations while expanding in underrepresented areas like the Pacific Northwest [7].
CVS Health(CVS) - 2025 Q2 - Quarterly Results
2025-07-31 10:31
Exhibit 99.1 CVS HEALTH CORPORATION REPORTS SECOND QUARTER 2025 RESULTS AND UPDATES FULL-YEAR 2025 GUIDANCE Financial Highlights Operational Highlights 2025 Full-Year Guidance CEO Commentary "What people want most — a connected, simpler health care experience — is what CVS Health uniquely provides. For the 185 million people we serve, we deliver better access, greater affordability and aligned advocacy. Our strong performance demonstrates the continued focus we have on operational and financial improvement ...
CVS HEALTH CORPORATION REPORTS SECOND QUARTER 2025 RESULTS AND UPDATES FULL-YEAR 2025 GUIDANCE
Prnewswire· 2025-07-31 10:30
Financial Highlights - Total revenues for the second quarter of 2025 reached $98.9 billion, an increase of 8.4% compared to the prior year [4][7] - Operating income decreased by 21.8% to $2.4 billion, primarily due to $833 million in litigation charges [8] - Adjusted operating income increased by 1.7% to $3.8 billion, driven by growth in the Health Care Benefits and Pharmacy & Consumer Wellness segments [8] - Diluted earnings per share (EPS) were $0.80, down from $1.41 in the prior year, while adjusted EPS was $1.81, relatively stable compared to the previous year [4][7] Operational Highlights - The Health Care Benefits segment reported total revenues of $36.3 billion, up from $32.5 billion, with adjusted operating income increasing significantly [10] - The Health Services segment's total revenues rose to $46.5 billion, but adjusted operating income decreased due to litigation charges [12] - The Pharmacy & Consumer Wellness segment saw total revenues increase to $33.6 billion, with adjusted operating income rising significantly [16] 2025 Full-Year Guidance - The company revised its GAAP diluted EPS guidance range to $3.84 to $3.94, down from $4.23 to $4.43 [7] - Adjusted EPS guidance was raised to a range of $6.30 to $6.40, up from $6.00 to $6.20 [7] - Cash flow from operations guidance was increased to at least $7.5 billion, up from approximately $7.0 billion [7] CEO Commentary - The CEO emphasized the company's commitment to providing a connected and simpler health care experience, highlighting strong performance across various segments [1][2] - The focus remains on operational and financial improvement, particularly in the Aetna and CVS Caremark segments [1][5] Additional Insights - The company announced a commitment of $20 billion over the next decade to simplify the U.S. health system [13] - CVS Pharmacy agreed to acquire certain prescription files and store locations from Rite Aid, enhancing its market position [13] - The company is actively working on initiatives to improve the experience for both doctors and patients [13]
Top Wall Street Forecasters Revamp CVS Health Expectations Ahead Of Q2 Earnings
Benzinga· 2025-07-31 07:35
Earnings Report - CVS Health is expected to report Q2 earnings of $1.46 per share, a decrease from $1.83 per share in the same period last year [1] - Projected quarterly revenue is $94.59 billion, up from $91.23 billion a year earlier [1] Recent Developments - CVS Health opened a new Workforce Innovation and Talent Center (WITC) in Columbus on July 23 [2] - CVS Health shares increased by 3.8%, closing at $62.30 on Wednesday [2] Analyst Ratings - UBS analyst Kevin Caliendo maintained a Neutral rating and reduced the price target from $71 to $67 [4] - Jefferies analyst Brian Tanquilut maintained a Buy rating and raised the price target from $74 to $80 [4] - Mizuho analyst Ann Hynes maintained an Outperform rating and increased the price target from $70 to $76 [4] - Leerink Partners analyst Michael Cherny upgraded the stock from Market Perform to Outperform and raised the price target from $55 to $75 [4]
Is CVS Health (CVS) Stock Outpacing Its Medical Peers This Year?
ZACKS· 2025-07-30 14:41
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is CVS Health (CVS) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question. CVS Health is one of 983 companies in the Medical group. The Medical group currently sits at #7 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measu ...
CVS Health Care Delivery: Will the Growth Momentum Last in Q2?
ZACKS· 2025-07-30 13:26
Core Insights - CVS Health's Health Care Delivery business has shown strong revenue growth, with a 27% increase in Q1 2025, driven by strategic acquisitions and a focus on value-based care [1][8] Group 1: Financial Performance - The Health Care Delivery segment's revenue growth of 27% in Q1 2025 excludes the impact of exiting certain programs and selling parts of the business [1] - Integration costs related to the acquisitions of Signify Health and Oak Street Health amounted to $45 million in Q1 2025 [2] - CVS Health's Signify unit completed over 3 million in-home health evaluations in 2024, while Oak Street reported a 37% increase in at-risk members [3][8] Group 2: Market Dynamics - The financial performance of the Health Care Delivery business is closely linked to Medicare Advantage medical cost trends, with early signs of pressure observed at Oak Street Health [4] - Humana's CenterWell segment reported a 37.5% revenue growth in Q1 2025, driven by primary care business expansion [5] - Agilon Health is transforming senior healthcare with its PalliUM program, which has seen increased patient participation [6] Group 3: Valuation and Estimates - CVS Health shares have increased by 6.2% over the past six months, contrasting with an 11.6% decline in the industry [7] - The stock is trading at a forward price-to-earnings ratio of 9.06, below the industry average of 14.37, and carries a Value Score of A [9] - Consensus estimates for CVS Health's 2025 earnings have shown an upward trend, with current estimates for Q1 2025 at $1.47 and for the full year at $6.12 [10][11]
Buy CVS Stock Ahead of Its Upcoming Earnings?
Forbes· 2025-07-30 13:15
Core Insights - CVS Health is set to announce its earnings on July 31, 2025, with historical stock behavior around earnings releases being a key focus for event-driven traders [2] - The consensus estimate for CVS's upcoming earnings is $1.46 per share on revenue of $94.59 billion, indicating a decline in profitability compared to the previous year [4][5] - CVS Health currently has a market capitalization of $76 billion and generated $379 billion in revenue over the last twelve months, with operating profits of $11 billion and net income of $5.3 billion [5] Historical Performance - Over the past five years, CVS stock has shown a tendency toward positive one-day returns post-earnings, with 55% of instances resulting in a positive return and a median gain of 4.4% [3][10] - There have been 20 earnings data points recorded in the last five years, with 11 positive and 9 negative one-day returns observed [6] - The percentage of positive returns increases to 58% when considering data from the last three years [10] Trading Strategies - Traders typically employ pre-earnings positioning, assessing historical probabilities before the earnings report, and post-earnings positioning, observing stock movements after the earnings release [7] - Understanding the correlation between short-term and medium-term returns post-earnings can inform trading strategies, particularly if 1D and 5D returns show high correlation [8][9]